CorMedix (US.CRMD)
资本配置审计 · 期间： 2010 – 2026
核心指标
US.CRMD · 同比： 2026 Q1 vs 2025 Q1
| 指标 | 数值 | 同比 |
|---|---|---|
| FCF Conversion | 98.3% | → |
| ROE | 8.8% | ↓ |
| Cash Conversion | 110.5% | ↑ |
| D/E Ratio | 0.33 | ↓ |
| Gross Margin | 82.5% | ↓ |
US.CRMD (CorMedix) | YoY: 2026 Q1 vs 2025 Q1 Metric Value YoY ---------------------------- FCF Conversion 98.3% → ROE 8.8% ↓ Cash Conversion 110.5% ↑ D/E Ratio 0.33 ↓ Gross Margin 82.5% ↓
核心指标
US.CRMD (CorMedix) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY----------------------------FCF Conversion 98.3% →ROE 8.8% ↓Cash Conversion 110.5% ↑D/E Ratio 0.33 ↓Gross Margin 82.5% ↓免费公司
AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies